Poster Index - OTS 2026 Oligo Meeting | Denver, Colorado *(updated 21 September)*

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-001	Monitoring of Base Excision Repair in Living Cells Using Chimeric D/L-DNA Molecular Beacons	Rosemarie Elloisa	Acero	Texas A&M University
P-002	Advancing Oligonucleotide Bioconjugation: Strategies for Peptide, Protein, and Antibody Conjugates	Shiva	Adhikari	LGC Axolabs
P-003	Conformational Analysis of Nucleic Acids for Optimizing DNA and RNA Topological Models	Alain	Ajamian	Chemical Computing Group
P-004	siRNA off target activity can induce severe CNS toxicity not predicted by in vitro screening	Sarah	Allen	UMass Chan Medical School
P-005	Inosine-based nucleobase engineering suppresses seed-dependent off-target effects through thermodynamic destabilization	Seongjin	An	Institute of Science Tokyo
P-006	Antisense Oligonucleotide–Based N-of-1 Therapy Development for a Leigh Syndrome Patient with an NDUFAF8 Splicing Defect	Yutaro	Asami	Boston Children's Hospital
P-007	Development and therapeutic evaluation of SNP-distinguishable siRNAs targeting KRAS mutations for pancreatic cancer liver metastasis models	Yoshimasa	Asano	The University of Tokyo
P-008	Detection and quantification of PS, MOE, OMe or 2'F modified ASO or siRNA in cells, tissue and biological matrices using modification-specific antibodies in immunoassays	Carl	Ascoli	Rockland Immunochemicals Inc.
P-009	Utilizing a TfR TransportVehicle for the Treatment of Alzheimer's Disease	Scarlett	Barker	Denali Therapeutics
P-010	Bifunctional siRNAs combining viral RNA targeting and innate immune activation against coronaviruses	Celine	Baron	Ludwig-Maximilians-University Munich
P-011	Cell-Type-Selective Functional Readouts for Extrahepatic RNAi Delivery	J. Philipp	Becker	UMass Chan Medical School
P-012	Advancing an Investigational lncRNA WISPER-Targeting ASO for Cardiac Fibrosis: From Nonclinical Proof-of-Concept to Phase 1 Evaluation	James	Karras	HAYA Therapeutics Inc
P-013	Utilizing in vitro neuronal cell culture models in the lead identification and optimization of Nucleic Acid Therapeutics for CNS Disorders	Luca	Blindzellner	Axolabs GmbH
P-014	Microwave-Assisted Liquid-Phase Deprotection of Heavily Modified Oligonucleotides	Brianna	Bramato	UMass Chan Medical School
P-015	Advancing RNAi Therapeutics: Integrated Strategies for Optimal Lead Identification and Effective Tissue Delivery	Johannes	Braun	Hoffman-La Roche

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-016	A Synthetic Extracellular Vesicle-Inspired Platform for Functional Brain Delivery of RNA	Austin	Brent	Griffith University
P-017	cityRNAs: Expanding the RNAi Skyline	Christopher	Brown	City Therapeutics
P-018	Developing Antisense Oligonucleotides (ASOs) Targeting LMNB1 for Personalized Treatment of the Neurodegenerative Disorder ADLD	Noga	Budick-Harmelin	Sheba Medical Center
P-019	SplintR ddPCR: Ultrasensitive Quantification of Nuclear ASO Exposure In Vivo	Peter	Burkard	BioMarin Pharmaceutical Inc.
P-020	A Modular Nucleic Acid Nanocapsule Targeting Chimera (NANTAC) Design for Targeted Protein Degradation	Rachelle	Canete	University of Connecticut
P-021	DeepRNAi: Toward Reducing Late-Stage Setbacks with a Frontier Model for siRNA Design	Scott	Findlay	Deep Genomics
P-022	Splice-switching Antisense Oligonucleotide Drug Discovery and Development for CLN3 Batten Disease	Jessica	Centa	Rosalind Franklin University of Medicine and Science
P-023	Characterization of terpene-enhanced endosomal escape of lipophilic siRNAs	Myriam	Cerezo-Magaña	Lund University
P-024	Divalent siRNA Architectures Silence Two Gene Targets in Human Skin	Maya	Chan	UMass Chan Medical School
P-025	Unimolecular Dual-Targeting siRNA for Improved Modulation of Skin Inflammation	Benjamin	Chang	UMass Chan Medical School
P-026	Reducing a Spliceosome Component to Repair Splicing: SYF2-Targeting ASOs Correct TDP-43 Pathology from iPSC Motor Neurons to In Vivo Proof-of-Concept in ALS/FTD	Wen-Hsuan	Chang	AcuraStem
P-027	Expansion of the Backbone Chemical Toolbox of the OPERA® Platform	Sayantan	Chatterjee	Korro Bio
P-028	Implementing institution-wide programs for the proactive identification and accelerated testing of genetic variants amenable to antisense oligonucleotide treatments	David	Cheerie	The Hospital for Sick Children
P-029	Full-length transcript sequencing maps RNA isoform diversity in primary human hepatocytes	Xinyuan	Chen	GSK
P-030	Phosphorothioate Chirality in Fully Chemically Modified CRISPR RNA Controls Cas9 Gene Editing	Ramadevi	Chilamkurthy	Wake Forest University School of Medicine

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-031	Advancing ASO Safety Assessment Through CNS-Relevant In Vitro Models	Laura	Colar Zanjko	BioTalentum Ltd
P-032	Precision RNAi for Fibrodysplasia Ossificans Progressiva: a combinatorial, unimolecular, allele selective approach	David	Cooper	UMass Chan Medical School
P-033	Automated On-Column Deprotection of Chemically Modified Oligonucleotides	William	Copp	Atalanta Therapeutics
P-034	Combining SAXS and Reactive MD Simulations to Uncover the Structure and Assembly of Crosslinked Surfactant Nanoparticles for Nucleic Acid Delivery	Patrick	Corrigan	University of Connecticut
P-035	Smarter siRNA Candidate Selection Through Scalable DRUG-seq Profiling	Kurt	Cox	Ginkgo Bioworks
P-036	Development of Oligonucleotide Tools Targeting TAF1 in X-linked Dystonia Parkinsonism	Caitlyn	Czinder	The University of Texas Medical Branch
P-037	3'-End Phosphate Contacts Drive Cas12a Editing Efficacy in Cells	Sabina	Dahal	The University of Texas Medical Branch
P-038	Tfr1-Aptamer Mediated siRNA Delivery to Skeletal Muscle Enables Robust and Specific Target Gene Silencing	Christopher	Dahlke	UMass Chan Medical School
P-039	Self-Assembled Spherical Nucleic Acids for Systemic siRNA Delivery Beyond the Liver	Trishalina	Das	McGill University
P-040	NMR Applications for Site-Specific Diastereomer Analysis in Oligonucleotides	Bibhuti	Das	Nitto Avecia
P-041	Cholic acid as a pharmacokinetic enhancer and a scaffold for RNA interference-based therapeutics	Dhrubajyoti	Datta	Alnylam Pharmaceuticals
P-042	Anti-RAGE Oligonucleotides Potentiate Immunotherapy in Glioblastoma	Mojtaba	Dayyani	City of Hope Beckman Research Institute
P-043	Development of Antisense Oligonucleotides for Treating an Individual with Delayed Onset CLN7 Batten Disease	Didem	Demirbas	Boston Children's Hospital
P-044	An Antisense Oligonucleotide Therapeutic Platform Approach for Haploinsufficient Monogenic Neurodevelopmental Disorders	Alexander	Diefes	Perelman School of Medicine, University of Pennsylvania
P-045	Adaptation of a Solid-Phase Peptide Synthesis Instrument for Automated Phosphorodiamidate Morpholino Oligomer (PMO) Synthesis	Amanda	Dombroski	Entrada Therapeutics

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-046	QTc Assessment of Golodirsen and Casimersen in Duchenne Muscular Dystrophy	Shuai	Dong	Sarepta Therapeutics, Inc.
P-047	Single-Nucleotide-Resolution Separation of Oligonucleotides up to 141 nt	Amanda	Edelson	SCIEX
P-048	NATx: An Academic Nucleic-Acid Synthesis Core to Support Translational Science	Michaela	Everly	University of Michigan - NATx Core
P-049	Purification of siRNA using reverse phase and anion exchange chromatography resins	Hadi	Fares	DuPont
P-050	Investigation of allele-selective antisense oligonucleotides: From design to delivery in patient derived myotubes	Kara	Farstad-O'Halloran	Harry Perkins Institute of Medical Research
P-051	Silencing ZNF410/BCL11A as therapeutic targets for fetal hemoglobin induction in β-haemoglobinopathies	Ayesha	Fatima	Aga Khan University
P-052	Large-scale manufacturing of siRNA by enzymatic ligation	Sabine	Fenner	Bachem AG
Cross-reference see P-021	*DeepRNAi: Toward Reducing Late-Stage Setbacks with a Frontier Model for siRNA Design*	*Scott*	*Findlay*	*DeepGenomics*
P-053	αvβ6-targeted siRNA delivery to the human lung to combat coronaviruses	Natalie	Fischhaber	Ludwig-Maximilians-University Munich
P-054	An ex vivo test system, with circulating human whole blood, enables immunotoxicity differentiation between imetelstat and inotersen	Erika	Fletcher	Immuneed AB
P-055	Beyond Symptomatic Relief: Modulating Osteoarthritis Progression with Combinatorial siRNA Therapeutics	Elizabeth	Flynn	UMass Chan Medical School
P-056	Engineering lipid-conjugated siRNAs for enhanced tissue distribution and gene silencing	Nora	Francini	Vanderbilt University
P-057	Concordance analysis of siRNA efficacy predictors reveals consensus for unmodified but not chemically modified designs	Daniel	Fuentes	Gordian Biotechnology
P-058	Internal cap-initiated translation provides efficient protein production from circular mRNA	Kosuke	Fukuchi	Graduate School of Science, Nagoya University
P-060	Allele-Specific ASOs as a Precision Therapeutic Strategy for AFG3L2-Related Disease	Aastha	Gandhi	University of Pennsylvania

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-061	Design and Synthesis of Next Generation Gapmer Antisense Oligonucleotides for Neurodegenerative Diseases	Atanu	Ghosh	McGill University
P-062	Improving the therapeutic index of ASOs and siRNAs for use in the lung through backbone modification and cyclic structure	Nathan	Gioacchini	UMass Chan Medical School
P-063	Probing and enhancing properties of linear cap-independently translated mRNA	Sebastian	Golojuch	University of Oxford
P-064	Systemic CNS Delivery of Oligonucleotides via Brain-Targeting Shuttles	James	Gorman	Wyss Institute, Harvard University
P-065	Next Generation RNA Aptamers: Advancing the Development of Therapeutic Aptamers	Bethany	Gray	Johns Hopkins University
P-066	Preclinical Evaluation of SRP-1003: An αvβ6 Integrin-Targeting, siRNA Platform for Targeted Knockdown of DMPK in Myotonic Dystrophy Type 1	Christopher	Greer	Sarepta Therapeutics, Inc.
P-067	siRNA-Mediated IL-1B Silencing as a Therapeutic Strategy for Deficiency of IL-1 Receptor Antagonist (DIRA)	Katherine	Gross	RNA Therapeutics Institute, UMass Chan Medical School
P-068	Challenging extra(telomeric) TERRA functions in Glioblastoma Stem Cells via LNP-delivered ASOs	Glenda Paola	Grupelli	CIBIO Department, University of Trento
P-069	siRNA Serum Half-Life Extension through Phosphoryl Guanidine (PN)-derived, Small Molecule-based Albumin Binders	Tobias	Haab	ETH Zürich
P-070	Novel sugar chemistries that broaden the RNA editing capabilities of the OPERA® platform	Adam	Hedger	Korro Bio
Cross-reference: ***See P-234***	*Scalable Platform Technology for Rapid, High-Quality Manufacturing of Neurological N-of-1 Splice-Switching Antisense Oligonucleotides*	*Seppe*	*Hermans*	*BianoGMP GmbH*
P-072	Development of a novel siRNA platform for pulmonary delivery, PulmoRNA, and its application to IL-33- and TSLP-targeting siRNAs	Chika	Higashi	Mochida Pharmaceutical
P-073	Preclinical Development of Allele-Selective Antisense Oligonucleotides for KCNQ2 Developmental and Epileptic Encephalopathy	Miwa	Higashi	Boston Children's Hospital
P-074	Antibody Oligonucleotide Conjugate Bioanalysis via Nucleic Acid Nanorobotics in Non-Human Primate Plasma Samples	Emily	Hoyt	Sanofi, Rare Diseases Therapeutic Area
P-075	An Integrated Discovery Platform for Accelerating Oligonucleotide Therapeutics via Advanced Conjugate Delivery Systems	Shanhu	Hu	WuXi AppTec

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-076	Designing a GRM7-specific BlockmiR oligonucleotide to target the repressive effects of microRNA-15a in Rett syndrome	Genevieve	Hunn	Vanderbilt University
P-077	ASOptimizer-Hepatox: A Deep Learning Model for ASO Hepatotoxicity Prediction	Gyeongjo	Hwang	Spidercore Inc.
P-078	siRNAnalyzer: A Deep Learning Model for siRNA Efficacy Prediction	Gyeongjo	Hwang	Spidercore Inc.
P-079	Structure-Activity Relationship of a Fully Modified MicroRNA-34a (FM-FolamiR-34a) Cancer Therapeutic	Shreyas	Iyer	Purdue University
P-080	Dynamic DNA nanotechnology in oligonucleotide quantification	Alexander	Jackson	Nanovery Limited
P-081	Comparison of continuous twin-column technology with single column batch methodology for the purification of an antisense oligonucleotide (ASO) using BioPro IEX Resins	Marc	Jacob	YMC America
P-082	MicroRNA-21: A Potential Therapeutic Agent Targeting Tgfbi and Mitigating High-Fat-Diet-Induced Liver Disease and Cancer	Urmila	Jagtap	Beth Israel Deaconess Medical Center
P-083	Intent™Xpress: A Highly Efficient, Stable LNP Transfection Reagent for Nucleic Acid Delivery into Cell Lines and Primary Human Immune Cells	Aarushi	Jain	Providence Therapeutics Holdings Inc.
P-084	SECN-15: An antisense oligonucleotide targeting neuropilin-1 overcomes immune checkpoint inhibitor resistance through remodeling of the tumor microenvironment	Frank	Jaschinski	Secarna Pharmaceuticals
P-085	(CA)n oligonucleotides correct RNA mis-splicing in TDP-43 pathology.	Lars	Joenson	Roche
Cross-reference: See P-233	*The SEDC Initiative: Accelerating Targeted RNA Therapeutics for Spondyloepiphyseal Dysplasia Congenita*	*Arthur*	*Johannpeter*	*SEDC*
P-086	Chemical Modification and Positional Patterning of Peptide Nucleic Acids for Splice-Switching: Applications in Neuromuscular Disease and Cancer	Narae	Joo	HLBPanagene
P-087	Process Development for ~100-mer sgRNA Manufacturing via SPOS	Minji	Kang	ST Pharm Co., Ltd.
Cross-reference: See P-012	*Advancing an Investigational lncRNA WISPER-Targeting ASO for Cardiac Fibrosis: From Nonclinical Proof-of-Concept to Phase 1 Evaluation*	*James*	*Karras*	*HAYA Therapeutics Inc*
P-088	Developing Personalized Antisense Oligonucleotide Therapies for Ultra-Rare Diseases: Early Experience from Four LUMC N-of-1 Programmes	Dyah	Karjosukarso	Leiden University Medical Center

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-089	A High-Throughput Encoded Oligonucleotide Pool Platform Coupled with AI/ML Modeling for Complement Activation Immunotoxicity Prediction in Antisense Oligonucleotide Development	Deepakshi	Kasat	GSK
P-090	Optimised Sample Preparation Strategies for LC-MS/MS Bioanalysis of GalNAc-Conjugated siRNA and Antisense Oligonucleotides	Stephanie	Keane	Resolian
P-091	Machine-learning prediction of chemically modified siRNA activity	Eric	Kercher	UMass Chan Medical School
P-092	COMPASS Integrates AI-Based Docking and Cell Imaging to Overcome Biomarker Identification Bottlenecks in Aptamer Discovery	Hyeokjung	Kim	University of Minnesota, Twin Cities
P-093	Chemically Modified mRNA based on Complete Chemical Synthesis for Enhanced Translation and Stability	Yasuaki	Kimura	Graduate School of Science, Nagoya University
P-094	Development of Highly Specific Aptamers targeting TfR1 and their Application to Oligonucleotide Drug Delivery	Tomoaki	Kirino	Mitsubishi Gas Chemical Company, Inc.
P-095	Selection and Characterization of DNA Aptamers for Inhibition of TDP-43 Aggregation in ALS	Daniel	Knight	Carleton University
P-096	A Gene-Agnostic Antisense Oligonucleotide for Inherited Retinal Disorders	Anders	Knudsen	Columbia University
P-097	Antisense Oligonucleotides Targeting Two Distinct Sites on DMD Exon 51 have a Synergistic Skipping Effect	Charles	Koehler	Keck Graduate Institute
P-098	Personalized ASO therapy for ALS associated with KIF5A mutations around exon 27: a multi-strategy approach	Ingrid	Kolen	Heidelberg University Hospital
P-099	Method Development for Quality Control of 2'-O-NMA Phosphoramidites – An AQbD Approach	Xiaoqing	Kong	Biogen
Cross-reference see P-234	*Efficient Conformational Sampling in Nucleic Acids Using LowModeMD*	*Wil*	*Krawszik*	*Chemical Computing Group*
P-100	Programming siRNA Delivery through Enzymatic Synthesis	Kalyanaraman	Krishnamoorthy	Codexis, Inc.
P-101	Evaluation of 3',4'-Cyclopropyl Monomers for Oligonucleotide Therapeutic Applications	Seetha	Krishnamoorthy	Genentech
P-102	Development of LCMS based methods for the detection and quantification of Antibody-Oligo Conjugates (AOCs) for in serum	Bhaskar	Kusuma	NJ Bio

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-103	Machine Learning-Accelerated Guide RNA Design for ADAR-Based Therapeutics	Sofia	Kyriazopoulou Panagiotopoulou	Deep Genomics
P-104	Development of an allele-specific antisense oligonucleotide therapeutic strategy for GNAI1-Related Neurodevelopmental Disorder	Dianne	Laboy Cintorn	St. Jude Children's Research Hospital
P-105	The Nucleic Acid Therapeutics (NATx) Core at the University of Michigan collaborates to develop tailored approaches for neurodevelopmental disease	Katelyn	Lacy	University of Michigan
P-106	Toward Full Chemical Modification of CRISPR RNA: Using Directed Evolution of Cas12a Ultra to Understand Structure-Function Mechanisms Underlying the 2'-Hydroxyl Barrier	Lydia	Larkai	Wake Forest University School of Medicine
P-107	Streamlining Therapeutic Actionability Assessments – The N=1 Collaborative Guidelines and Gene Registry	Marlen	Lauffer	University of Oxford
P-108	The STRIKE Platform Enables Safe and Efficacious Delivery of siRNA to Kidney Across Species	Jonathan	Lawrence	Judo Bio
P-109	UNLOCKING THE BLOOD-BRAIN-BARRIER: Systemic delivery of antisense oligonucleotide targeting ataxin-2 to treat ALS.	Liouba	Le Roux	The Florey Institute
P-110	Characterizing and Improving the Activity of GC-Rich Small Interfering RNAs	Shirley	Lee	RNA Therapeutics Institute, UMass Chan Medical School
P-111	Accelerating Peptide-Oligonucleotide Conjugate (POC) Programs by Overcoming Complex Synthesis Challenges	Yi	Lei	WuXi TIDES, part of WuXi AppTec
P-112	Beyond the Liver: A Proprietary Lung Epithelium-Targeting Ligand Platform Enabling Inhaled, Lung-Restricted Conjugate-siRNA（GW908） Silencing of RAGE for COPD and Asthma from Chengdu Gowell Pharma	Qingran	Li	Chengdu Gowell Biopharmaceutical Co., Ltd.
P-113	Novel Hepatic-Targeted siRNA for Lipoprotein(a) Lowering: A Promising Candidate in Phase I Clinical Trial	Yunping	Li	Chengdu Xuyuan biomedical
P-114	Cardioprotective small noncoding RNA from human iPSC-secreted extracellular vesicles	Junlang	Li	Cedars-Sinai Medical Center
P-115	Argonaute Paralog Dependency of GalNAc-siRNA Off-Target Hepatotoxicity: Ago2-Dominant versus pan-Ago Mechanisms	Hongda	Li	Ionis Pharmaceuticals
P-116	Preclinical efficacy of ENTR-801 for the treatment of USH2A-associated retinitis pigmentosa amenable to exon 13 skipping	Pingjuan	Li	Entrada Therapeutics
P-117	Engineering Intron Ribozymes to Generate Nucleoside-Modified Circular mRNA	Xiaoge	Liang	University of Michigan

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-118	Multiplexed In Vivo Discovery Platform Enables Rapid Discovery of Tissue-Targeted Shuttles for Optimized Oligonucleotide Therapeutic Delivery	Noa	Liberman	Manifold bio
P-119	An oligonucleotide design platform for ADAR-guided mRNA editing	Nina	Ligthart	ProQR Therapeutics
P-120	High Efficiency UV In-line Process Analytical Technology for Solid Phase Synthesis of Oligonucleotides	Ming-Chun	Lin	Industrial Technology Research Institute, Hsinchu
P-121	Preclinical Efficacy of ENTR-601-51 for the Treatment of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy	Haoming	Liu	Entrada Therapeutics
P-122	AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies	Chang	Liu	Sir Run Run Shaw Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine
P-123	A synthetic CAG repeat DNA model for measuring binding, stabilization, and cytosine flipping associated with the naphthyridine 8-azaquinolone molecule	John	Lucas	UMass Chan Medical School
P-124	Finding the Right Depot: Deep learning-designed ligands allow for receptor-mediated, siRNA delivery to selective adipose tissue	Kyler	Lugo	Nosis Biological Sciences
P-125	Engineering guide RNA for efficient ADAR editing	Sicong	Ma	University of Michigan
P-126	Engineering Circular Small Nucleic Acid (CSNA) Structures for RNAi Therapeutics	Sumit	Mahajan	Genentech, Inc
P-127	One platform, many tissues: deep learning-designed ligands reveal key attributes for extrahepatic siRNA delivery	Penny	Mahoney	Nosis Biological Sciences
P-128	CNS-selective siRNA co-modulation of APOE and JAK1 in advanced 5xFAD murine Alzheimer's Disease model	Katya (Yekaterina)	Makeyeva	UMass Chan Medical School
P-129	31P NMR Enables Quantitative Assessment of Phosphorothioate Stereochemistry in Antisense Oligonucleotide Therapeutics	Akanksha	Manghrani	National Institute of Standards and technology
P-130	Individualized Splice-Switching Antisense Oligonucleotide Design for a Deep Intronic Variant in DLG4-associated Neurodevelopmental Disorder	Alysia	Martinez	Boston Children's Hospital
P-131	miR-425-5p Regulates Cellular Senescence Through Modulation of Retinoblastoma Protein Phosphorylation	Latika	Matai	Beth Israel Deaconess Medical Center
P-133	Mesylphosphoramidate modification enhances CNS exposure and prolongs duration of effect of gapmer antisense oligonucleotides across species	Madelyn	McCauley	Ionis Pharmaceuticals

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-134	Extraction of siRNAs and Their Metabolites from Mouse Tissue Lysates for Quantification Using Triple Quadrupole Mass Spectrometry (TQ-MS)	Nicholas	McHugh	UMass Chan Medical School
P-135	Building a Next-Generation, Scalable Patient-Derived Neuronal Platform for Rapid n-of-1 ASO Therapeutic Discovery	Craig	McIntosh	n-Lorem Foundation
P-136	Targeted Delivery of Tumor-Suppressive miRNA-34a for Specific Osteosarcoma Therapy	Iman	Mevaa	Department of Biological Sciences, Purdue University
P-137	AI-guided ASO design integrating knockdown efficacy, immune stimulation, tolerability, and specificity	Sven	Michel	Secarna Pharmaceuticals
P-138	A triple-targeting trivalent siRNA as a therapeutic for Huntington's disease	Rachael	Miller	UMass Chan Medical School
P-139	Tertiary Alkylphosphonate Oligonucleotides: A Novel Backbone Modification Enabled by Photoredox Radical-Polar Crossover Chemistry	Naoya	Miyamoto	Takeda Pharmaceutical Company Limited
P-140	Hydrophilic Additive-Assisted Reversed-Phase Ion-Pair LC/MS for HFIP-Free Oligonucleotide Analysis	Takashi	Miyazaki	The University of Osaka
P-141	Development of splice-correcting ASOs for POLR3A-related leukodystrophy: toward Korea's first individualized oligonucleotide therapeutic	Jangsup	Moon	Seoul National University Hospital
P-142	Using "promiscuous" siRNAs to understand the biological limits of hybridization-dependent siRNA off-target interactions	Eliot	Morrison	Silence Therapeutics
P-143	Advancing the siRNA Platform through MCE-Modified Nucleotides and Programmable Phosphoramidate Backbone Modifications	Miyako	Naganuma	Nissan Chemical Corporation
P-144	A scalable platform for exon-skipping antisense oligonucleotide therapy development for inborn genetic diseases	Logan	Newton	The Hospital for Sick Children
P-145	Combining Solid-Phase Synthesis with Enzymatic Strategies enables High-Yield Synthesis of Capped RNA, long RNA, and circular RNA/DNA for Therapeutic and Diagnostic Applications	Tri	Ngo	Biosynthesis Inc.
P-146	Development and Qualification Comparisons of Two Hybridization LBA Methods for siRNA Quantification.	Liz	Nolff	BioAgilytix
P-147	Bottlebrush polymer conjugates for enhanced antisense oligonucleotide therapy in myotonic dystrophy type 1	Christopher	Oetheimer	Northeastern University
P-148	PYC-002: an RNA drug candidate for the treatment of Phelan-McDermid Syndrome	Wontaek	Oh	PYC Therapeutics
P-149	STMN2-Targeted Oligonucleotides with Improved Therapeutic Index for Sporadic ALS	Masahiro	Ohara	RNA Therapeutics Institute, UMass Chan Medical School

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-150	From Oligonucleotides to AOCs: Leveraging Diverse Conjugation Strategies and WuXiDAR1 Technology to Enable Next-Generation Targeted Delivery	Jack	Yang	WuXi XDC
P-151	Activating TCF4 Expression Using Promoter-Targeted Duplex RNAs	Sonya	Ostashevskaya-Gohstand	UT Southwestern Medical Center
P-152	Orthogonal Assessment by CD, Raman, and IR Spectroscopy Reveals Concentration-Dependent Polymorphism of Nucleic Acid Higher-Order Structures	Taiji	Oyama	JASCO Corporation
P-153	Fluorescent Nucleoside Analogues as Minimally Perturbing Probes for Oligonucleotide Structure, Dynamics, and Cellular Fate	Bhoomika	Pandit	San Diego State University
P-154	An LLM-orchestrated agent for autonomous antisense oligonucleotide design	Deepak	Pant	University of California San Diego
P-155	Development of antisense oligonucleotides (ASOs) as therapeutics to treat primary ciliary dyskinesia (PCD)	Vanesa	Papastavrou	University College London
P-156	Peptide-conjugated PMOs enhance splice correction and functional rescue in a humanized mouse model of dysferlinopathy	Gyeongsu	Park	UMass Chan Medical School
P-157	CJ-1: An Optimized mRNA Platform with Enhanced Protein Expression and Minimal Immunogenicity for Therapeutic Applications	Hyun	Park	Korea Research Institute of Bioscience and Biotechnology
P-158	Size Exclusion Coupled with Mass Spectrometry (SEC-MS) for Early OAR Characterization of Antibody–Oligonucleotide Conjugates (AOCs)	Tran	Pham	Phenomenex
P-159	Structural engineering of dual-targeting antisense oligonucleotides enhances exon 44 skipping for treating Duchenne muscular dystrophy	Justin	Pi	David Geffen School of Medicine, UCLA
P-160	Assessment of acute and delayed onset toxicity effects of oligonucleotides using in vitro neuronal models	Johan	Pihl	Cellectricon AB
P-161	Systemic delivery of antimiR-23b as a therapy targeting MBNL dysfunction across repeat expansion disorders	Diego	Piqueras-Losilla	ARTHEx Biotech
P-162	Stabilin-1 and Stabilin-2: Systemic clearance receptors for antisense oligonucleotides	Linda	Pratt	University of Nebraska
P-163	REACH: An innovative chemistry platform for enhanced productive uptake of ASOs in the CNS	Piotr	Putaj	Vico Therapeutics
P-164	Evaluating siRNA Delivery Under Inflammatory Conditions	Mohamad Omar	Rachid	UMass Chan Medical School
P-166	miR-34a Exacerbates Ischemic Stroke Injury and Represents a Novel Therapeutic Target	Xuefang	Ren	UTHealth Houston
P-167	A Robust ELISA-Like Hybridization Assay for the Detection of Therapeutic Oligonucleotides	Nicholas	Rice	Advirna
P-168	Targeting telomerase RNA with thiomorpholino antisense oligonucleotides for cancer therapy	Julieta	Rivosecchi	University of Colorado Boulder
P-169	Ligand mediated RNAi for cancer associated fibroblast reprogramming as a therapeutic strategy in lung cancer	Alejandra	Romero Alzate	Purdue University Department of Biological Sciences

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-170	Optimization of ASO Chemical Modification Patterns Using Generative Machine Learning Models	Rachapun	Rotrattanadumrong	Pharma Research and Early Development, F. Hoffmann-La Roche
P-171	Nucleic Acid Nanocapsule Targeting Chimeras (NAN-TACs): a synergistic approach for gene regulation and combined targeted protein degradation	Jessica	Rouge	University of Connecticut, Department of Chemistry
P-172	Janus Base Nanoparticles (JBNps): A Versatile DNA-Inspired Platform for Delivery of Short and Long Nucleotide Therapeutics	Ian	Sands	Eascra Biotech
P-173	Designing an allele-selective antisense therapy for CLN4 Batten, an adult-onset neurodegenerative disease	Samantha	Sarli	Boston Children's Hospital
P-174	The Histone Stem-Loop as a Supplement and Alternative to Poly-A for Therapeutic mRNAs	Emmanuel	Sasu	Wake Forest University School of Medicine
P-175	Development of the Endosomal Escape Vehicle (EEV™) Platform for Enhanced Delivery of Oligonucleotides to Skeletal and Cardiac Muscle	Mark Xiulong	Shen	Entrada Therapeutics
P-176	RNA editing of PNPLA3 I148M decreases hepatocyte lipid droplet content	Chikdu	Shivalila	Wave Life Sciences
P-177	Identification of First-Generation ssDNA Aptamers Against Human Adenosine Deaminase 2 (ADA2)	Garima	Shrivastava	Duke University, School of Medicine
P-178	Exploring 2' hydrogen bond replacement in CRISPR-Cas enzymes with 2' halogen bonds	Bhagat	Singh	Wake Forest University School of Medicine
P-179	Endolysosomal Sequestration Limits Productive Delivery of Naked Antisense Oligonucleotides	Ewa	Sitarska	Harvard Medical School
P-180	Autonomous, data-driven discovery of intronic target sites for gene expression upregulation by oligonucleotide therapeutics	Geoffrey	Siwo	University of Michigan
P-181	Preclinical development of antisense oligonucleotide therapy for rare kidney disease	Sebastian	Sjöström	ETH Zürich
P-182	Molecular microdissection of pathological RNA aggregates in Huntington's Disease	Nicholas	Skiados	University of Washington
P-184	Real-world safety of commercially approved ASOs: An analysis of safety outcomes in 2,950 US patients who have received ASO in the post-approval setting	Rachel	Smith	Parexel International
P-185	Rational Thermodynamic Design of Hybridization Probes for siRNA Quantification	Terutaka	Sonohara	PK and PD Research Laboratories, Daiichi Sankyo Co., Ltd.
P-186	Antibody–Oligonucleotide Conjugates (AOCs) – from Synthesis to Bioanalytical Evaluation	Kristina	Spieß	Axolabs GmbH
P-187	A novel approach to inhibit TSH-receptor signaling as a potential treatment for Graves' disease	Christiaan	Stavast	Erasmus University Medical Center
P-188	Streamlined Solid-Phase Synthesis of Peptide–Oligonucleotide Conjugates via Direct Elongation. Kavitha Sudheendra, Moussa Barzani, Klaus D. Linse, and Miguel Castro*, Bio-Synthesis Inc, 800 Mario Ct, Lewisville, TX 75057	Kavitha	Sudheendra	Biosynthesis Inc.

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-190	Routine LC–MS Characterization of sgRNA and siRNA Using an Extended Mass Range Single-Quadrupole MS	Risa	Suzuki	Shimadzu Scientific Instruments
P-191	Programmable Gene Upregulation Through 3' UTR-Targeted RNA Hacking Using Staple Oligomer	Ririka	Taniguchi	Faculty of Advanced Science and Technology, Kumamoto University
P-192	Accelerating N-of-1 Therapy: A Cell-Free High-Throughput ASO Screening	Laura	Teodori	ETH Zurich
P-193	Local Delivery Approach for Central Nervous System Diseases Using BROTHERS™ Antisense Oligonucleotides	Chisato	Terada	Liid Pharmaceuticals, Inc
P-194	Optimizing siRNA Architecture for Long-Acting RNAi Therapeutics in Skin	Sean	Thackeray	RNA Therapeutics Institute, UMass Chan Medical School
P-195	Leveraging Single-Cell RNA Sequencing to Design Next Generation Cartilage-Targeting siRNA Conjugates	Brennen	Thomas	Vanderbilt University
P-196	Strategies to improve the delivery of synthetic therapeutic oligonucleotides to muscle tissue	Alba	Timón-Gómez	Biomedical Research Networking Center Consortium in Rare Diseases, CIBERER
P-197	From cell-based screening to in vivo evaluation of HPPD-targeted ASOs in hereditary tyrosinemia type I	Tomasz	Tomkiewicz	Great Ormond Street Institute of Child Health, University College London
P-198	HSPB8 targeting and modulation – a multimodality approach for an ultrarare muscle disorder	Blanca	Torroba	IQVIA Laboratories
P-199	SORT1-Mediated Delivery of siRNA Conjugates to the CNS for Overcoming Treatment Resistance in Glioblastoma Multiforme.	Shannon	Tsai	ProteinQure
P-200	Investigating a role for nuclear microRNAs in splicing regulation	Victor	Tse	UT Southwestern Medical Center
P-201	Antisense oligonucleotides targeting MUC1 as a therapeutic approach for rare genetic kidney disease	Wei Chou	Tseng	Broad Institute
P-202	A Subset of TRiM-Ago2 Drives mRNA Knockdown	Chun-CHe	Tseng	Arrowhead Pharmaceuticals
P-203	Engineering Ligand-Conjugated siRNAs to Enhance Extrahepatic Gene Silencing	Keiji	Uehara	Kyowa Kirin Co., Ltd.
P-204	Antisense Oligonucleotide–Mediated Substrate Reduction Therapy Ameliorates Molecular and Neurological Pathology in MPSIIIA Models	Noam	Vaknin	Sheba Medical Center
P-205	Directly differentiated neuronal models to identify molecular signatures and therapeutic targets in familial Amyotrophic Lateral Sclerosis	Vamshidhar	Vangoor	University Medical Center Utrecht Brain Center
P-206	Systematic Evaluation of Phosphorothioate Linkages in Designing Efficient Splice Switching Antisense Oligonucleotides.	Rakesh	Veedu	Murdoch University & Perron Institute
P-207	Redundant siRNA Pools Overcome Viral Sequence Diversity	Julian	Vogler	LMU University Hospital
P-208	Fully Modified SpyCas9 Guide RNAs Enable Robust Genome Editing In Cells and In Vivo	Kim Ahn	VU	UMass Chan Medical School

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-209	Decoding RNA Biology to Enable Effective ASO Design for Precision Gene Upregulation	Anthony	Vu	n-Lorem Foundation
P-210	Construction of Chimeric Artificial Nucleic Acids (CANA) for Pancreatic Cancer Treatment by Inhibiting the Transcription Factor BACH1: Molecular Design Strategy Based on in vitro and in vivo Analysis	Takehiko	Wada	NICHe, Tohoku University
P-211	Circularly structured guide RNAs boost genome editing potency in vivo and in vitro	Atish	Wagh	RNA Therapeutics Institute, UMass Chan Medical School
P-212	Vehicle-Free PSMA-Targeted Delivery of Fully Modified miR-34a Enables Efficient Prostate Cancer Targeting and Extended Pharmacokinetics	Digambar	Waiker	Department of Biological Sciences, Purdue University
P-213	Generation of Humanized ALK7 Mice for Obesity Preclinical Research and Small Nucleic Acid Drug Evaluation	Qiurong	Wang	Biocytogen
P-214	A Humanized INHBE Mouse Model Enabling Preclinical Assessment of RNAi Therapeutics	Qiurong	Wang	Biocytogen
P-215	Allele-Selective ASO Knockdown Rescues Dominant-Negative Spectrin Aggregation in SPTAN1 Developmental and Epileptic Encephalopathy	Christiana	Wang	Baylor College of Medicine
P-216	mRNA half-life is a key determinant of siRNA efficacy in vivo	Kyle	Weirether	Alnylam Pharmaceuticals
P-217	Predicting Fully Chemically Modified CRISPR-Cas12a Guide RNAs with Physics-Informed Computation and Machine Learning	Adam	White	Wake Forest University School of Medicine
P-218	In vitro-In vivo Extrapolation of GalNAc siRNA Hepatic metabolic clearance	Christopher	Wiethoff	Eli Lilly & Company
Cross-reference See P-150	*From Oligonucleotides to AOCs: Leveraging Diverse Conjugation Strategies and WuXiDAR1 Technology to Enable Next-Generation Targeted Delivery*	*Jack*	*Yang*	*WuXi XDC*
P-220	Force Field Parameterization for Accurate Modeling of π–π Stacking Interactions in Nucleic Acids	Lynn Samira	Yamout	McGill University
P-221	mRNAutilus: Multi-Objective-Guided Discrete Generation of mRNA with Optimized Therapeutic Properties	Sherwood	Yao	Atom Bioworks Inc.
P-222	Accelerating Hit-to-Lead Discovery for OligonucleotideTherapeutics Using an Integrated Platform	Hongran	Yin	Synoligo Biotechnologies
P-223	Interferon-induced ADAR1p150 remodels Dicer complexes to selectively regulate miRNA biogenesis	Toyotaka	Yoshida	Institute of Science Tokyo

		Presenter		
Poster #	Title	First Name	Last Name	Affiliation
P-224	Guanine-base modifications in antisense oligonucleotides mitigate in vivo neurotoxicity.	Kotaro	Yoshioka	Institute of Science Tokyo
P-225	An Integrated Service Platform to Support the Discovery of Dual-Targeting Oligonucleotide Drugs to Treat Elevated ASCVD Risk in Diabetes	Ying	Yu	WuXi Biology, WuXi AppTec
P-226	SAR-guided lead optimization of tRNA-based therapeutics for rare diseases	Jonah	Zarrow	Cedars-Sinai Medical Center
P-227	From Imbalance to Equilibrium: Antisense Oligonucleotide Therapy Targeting Allelic Expression of PEX6 in Zellweger Spectrum Disorder	Evelyn	Zavacky	McGill University
P-228	Novel CD98hc-Targeting Antibodies for Blood-Brain Barrier Penetration	Jay	Zhang	Biocytogen
P-229	Brushield: A Long-Circulating Bottlebrush Polymer Platform for Extrahepatic Oligonucleotide Delivery	Ke	Zhang	Northeastern University
P-230	Kodexia: Scaling the Future of siRNA with Generative AI	Honggen	Zhang	XtalPi
P-231	A Small Binding RNA Therapeutic Approach for Allele-Selective Mutant HTT and HTT1a Silencing in Huntington's Disease	Chi	Zhang	Iris Medicine
P-232	Targeting Disease Causing Small RNAs with Allele-Selective ASO Therapeutics	Wei	Zhang	n-Lorem Foundation
P-233	The SEDC Initiative: Accelerating Targeted RNA Therapeutics for Spondyloepiphyseal Dysplasia Congenita	Arthur	Johannpeter	SEDC
P-234	Scalable Platform Technology for Rapid, High-Quality Manufacturing of Neurological N-of-1 Splice-Switching Antisense Oligonucleotides	Seppe	Hermans	BianoGMP GmbH
P-235	Efficient Conformational Sampling in Nucleic Acids Using LowModeMD	Wil	Krawszik	Chemical Computing Group